Assessing the Behavior of Met DR in Subjects With Kidney Dysfunction
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
This study evaluated how a single dose of delayed-release metformin (Met DR) behaves in
subjects with normal kidney function, mild kidney dysfunction, moderate kidney dysfunction,
or severe kidney dysfunction. The safety and tolerability of Met DR was also examined. In
addition, this study compared the behavior of a single dose of Met DR with that of
extended-release metformin (Met XR) and placebo in subjects with the varying levels of kidney
function described above.